Overview of HIV infection

Annals of Allergy, Asthma and Immunology

Volumn 83, Issue 1, 1999, Pages 1-7

  Temesgen, Zelalem ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

DEVELOPING COUNTRY; DRUG COST; EPIDEMIC; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERTRIGLYCERIDEMIA; INDUSTRIALIZATION; NEPHROLITHIASIS; OPPORTUNISTIC INFECTION; PARESTHESIA; PREGNANCY; PRIORITY JOURNAL; REVIEW; WORLD HEALTH ORGANIZATION;

EID: 0033507545     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1081-1206(10)63503-x     Document Type: Review

References (33)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO) Report on the global HIV/AIDS epidemic, June 1998.
2. Centers for Disease Control and prevention. HIV/AIDS Surveillance Report. 1997;9:2.
3. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-358.
4. Embretson J, Zupancic M, Ribas JL, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993;362:359-362.
5. Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-1586.
6. Ho DD, Neumann AU, Perelson AS. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126.
7. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-122.
8. Mulder J, Mckinney N, Christopherson C, et al. A rapid and simple PCR assay for quantification of HIV-1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994; 32:292-300.
9. Pachl C, Todd HA, Kern DG, et al. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. J Acquir Immune Defic Syndr 1995;8:446-454.
10. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122: 573-579.
11. Mellors JW, Rinaldo CR, Gupta P, et al. Prognosis of HIV-1 infection predicted by quantity of virus in plasma. Science 1996;272:1167-1170.
12. Welles SL, Jackson JB, Yen-Lieberman B, et al. Prognostic value of plasma human immunodeficiency virus type I (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. J Infect Dis 1996;174: 696-703.
13. Coombs RW, Welles SL, Hooper C, et al. Association of plasma human immunodeficiency virus type I RNA level with risk of clinical progression in patients with advanced HIV infection. J Infect Dis 1996;174:704-712.
14. O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996;334:425-431.
15. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV infected individuals with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996;335: 1091-1098.
16. Saag MS, Holodniy M, Kuritzkes DR, et al. HIV viral load markers in clinical practice. Nature Med 1996;2:625-629.
17. CAESAR Coordinating Committee. Randomized trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial. Lancet 1997;349: 1413-1421.
18. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 Protease inhibitors: a review for clinicians. JAMA 1997; 277:145-153.
19. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996; 335:1081-1090.
20. Delta Coordinating Committee. Delta: a randomized double blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996;348: 283-291.
21. Saravolatz LD, Winslow DL, Collins G, et al. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected individuals with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 1996;335: 1099-1106.
22. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337(11):725-733.
23. Carpenter CJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA panel. JAMA 1998;280: 78-86.
24. US Department of Health and Human Services and the Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. MMWR Morb Mortal Wkly Rep 1998;47(RR-05):43-82.
25. Centers for Disease Control and Prevention. US Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. MMWR Morb Mortal Wkly Rep 1995; 44(RR-7):1-14.
26. Centers for Disease Control and Prevention. Recommendations of the Public Health Service Task Force on use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1994;43(RR-11):1-21.
27. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-1180.
28. US Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women for maternal health and reducing perinatal HIV-1 transmission in the United States. MMWR Morb Mortal Wkly Rep 1998;47(RR-02):1-30.
29. Bell DM. Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview. Am J Med 1997;102(suppl 5B):9-15.
30. Ippolito G, Puro V, De Carli G. The risk of occupational human immunodeficiency virus infection in health care workers. The Italian study group on occupational risk of HIV infection. Arch Intern Med 1993;153: 1451-1458.
31. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med 1997;337:1485-1490.
32. Centers for Disease Control and Prevention. Update: provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR Morb Mortal Wkly Rep 1996;45:468-472.
33. Centers for Disease Control and Prevention. Public Health Service guidelines for the management of health care worker exposures to HIV and recommendations for postexposure prophylaxis. MMWR Morb Mortal Wkly Rep 1998;47(RR-7):1-33.